Caprock Group’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.13M | Sell |
213,162
-37,494
| -15% | -$981K | 0.1% | 165 |
|
|
2026
Q1 | $7.04M | Buy |
250,656
+49,447
| +25% | +$1.32M | 0.17% | 98 |
|
|
2025
Q4 | $5.01M | Sell |
201,209
-17,489
| -8% | -$441K | 0.11% | 165 |
|
|
2025
Q3 | $5.51M | Buy |
+218,698
| New | +$5.4M | 0.14% | 123 |
|
|
2025
Q1 | $3.42M | Buy |
135,003
+25,809
| +24% | +$675K | 0.1% | 174 |
|
|
2024
Q4 | $2.9M | Sell |
109,194
-60,781
| -36% | -$1.65M | 0.09% | 185 |
|
|
2024
Q3 | $4.92M | Sell |
169,975
-1,384
| -0.8% | -$40.4K | 0.18% | 91 |
|
|
2024
Q2 | $4.79M | Buy |
171,359
+72,818
| +74% | +$2M | 0.2% | 81 |
|
|
2024
Q1 | $2.73M | Buy |
98,541
+2,907
| +3% | +$80.7K | 0.16% | 91 |
|
|
2023
Q4 | $2.75M | Buy |
95,634
+35,063
| +58% | +$1.06M | 0.18% | 87 |
|
|
2023
Q3 | $2.01M | Sell |
60,571
-3,094
| -5% | -$109K | 0.15% | 97 |
|
|
2023
Q2 | $2.34M | Buy |
63,665
+1,759
| +3% | +$68.5K | 0.17% | 89 |
|
|
2023
Q1 | $2.53M | Buy |
61,906
+22,487
| +57% | +$971K | 0.2% | 78 |
|
|
2022
Q4 | $2.02M | Buy |
39,419
+4,681
| +13% | +$224K | 0.19% | 86 |
|
|
2022
Q3 | $1.52M | Buy |
34,738
+4,225
| +14% | +$205K | 0.15% | 102 |
|
|
2022
Q2 | $1.6M | Buy |
30,513
+8,419
| +38% | +$429K | 0.16% | 98 |
|
|
2022
Q1 | $1.14M | Buy |
22,094
+1,016
| +5% | +$52.7K | 0.11% | 149 |
|
|
2021
Q4 | $1.25M | Sell |
21,078
-40,264
| -66% | -$1.99M | 0.1% | 147 |
|
|
2021
Q3 | $2.64M | Sell |
61,342
-309
| -0.5% | -$13.7K | 0.24% | 65 |
|
|
2021
Q2 | $2.41M | Sell |
61,651
-615
| -1% | -$23.9K | 0.22% | 74 |
|
|
2021
Q1 | $2.26M | Sell |
62,266
-580
| -0.9% | -$20.6K | 0.25% | 70 |
|
|
2020
Q4 | $2.31M | Sell |
62,846
-5,159
| -8% | -$189K | 0.26% | 66 |
|
|
2020
Q3 | $2.37M | Sell |
68,005
-16,459
| -19% | -$577K | 0.32% | 55 |
|
|
2020
Q2 | $2.62M | Buy |
84,464
+8,402
| +11% | +$285K | 0.39% | 47 |
|
|
2020
Q1 | $2.35M | Buy |
76,062
+59,491
| +359% | +$2.03M | 0.45% | 42 |
|
|
2019
Q4 | $616K | Buy |
16,571
+1,111
| +7% | +$39.6K | 0.11% | 139 |
|
|
2019
Q3 | $527K | Sell |
15,460
-4,269
| -22% | -$155K | 0.1% | 148 |
|
|
2019
Q2 | $811K | Sell |
19,729
-52,684
| -73% | -$2.09M | 0.16% | 113 |
|
|
2019
Q1 | $2.92M | Sell |
72,413
-1,101
| -1% | -$44.1K | 0.57% | 34 |
|
|
2018
Q4 | $3.04M | Sell |
73,514
-1,676
| -2% | -$69.6K | 0.7% | 26 |
|
|
2018
Q3 | $3.14M | Sell |
75,190
-3,922
| -5% | -$151K | 0.64% | 26 |
|
|
2018
Q2 | $2.72M | Sell |
79,112
-10,821
| -12% | -$370K | 0.58% | 26 |
|
|
2018
Q1 | $3.03M | Sell |
89,933
-2,627
| -3% | -$90.3K | 0.65% | 25 |
|
|
2017
Q4 | $3.21M | Sell |
92,560
-13,105
| -12% | -$447K | 0.62% | 26 |
|
|
2017
Q3 | $3.58M | Buy |
105,665
+1,810
| +2% | +$58.2K | 0.75% | 22 |
|
|
2017
Q2 | $3.31M | Buy |
103,855
+7,905
| +8% | +$249K | 0.74% | 25 |
|
|
2017
Q1 | $3.11M | Sell |
95,950
-6,573
| -6% | -$207K | 0.73% | 26 |
|
|
2016
Q4 | $3.16M | Sell |
102,523
-17,507
| -15% | -$534K | 0.79% | 25 |
|
|
2016
Q3 | $3.86M | Buy |
120,030
+7,119
| +6% | +$238K | 0.87% | 24 |
|
|
2016
Q2 | $3.77M | Sell |
112,911
-3,721
| -3% | -$119K | 0.92% | 27 |
|
|
2016
Q1 | $3.28M | Buy |
116,632
+93,367
| +401% | +$2.67M | 0.78% | 27 |
|
|
2015
Q4 | $713K | Hold |
23,265
| – | – | 0.41% | 42 |
|
|
2015
Q3 | $693K | Sell |
23,265
-142
| -0.6% | -$4.55K | 0.49% | 36 |
|
|
2015
Q2 | $745K | Sell |
23,407
-17
| -0.1% | -$554 | 0.68% | 34 |
|
|
2015
Q1 | $773K | Hold |
23,424
| – | – | 0.79% | 29 |
|
|
2014
Q4 | $692K | Buy |
+23,424
| New | +$672K | 0.75% | 31 |
|
Other funds holding PFE
Caprock Group's PFE Position: Q2 2026 in Review
Caprock Group reduced its Pfizer (PFE) stake by 15% in Q2 2026, selling an estimated $981K and leaving 213,162 shares worth $5.13M. The position accounts for 0.1% of the portfolio, ranked #165.
Caprock Group first reported a position in PFE in Q4 2014 and has held it in 46 quarters since. The position peaked at $7.04M in Q1 2026. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Caprock Group held 213,162 shares of Pfizer worth $5.13M as of Q2 2026.
- Caprock Group sold 37,494 Pfizer shares in Q2 2026, an estimated $981K.
- Pfizer made up 0.1% of Caprock Group's portfolio in Q2 2026, its #165 holding.
- Caprock Group first reported a position in Pfizer in Q4 2014 and has held it in 46 quarters since.
- Caprock Group's Pfizer position peaked at $7.04M in Q1 2026.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Caprock Group's 13F filing for Q2 2026, filed 27 Jul 2026.